Director

August J. Moretti

Former Chief Financial Officer·4D Molecular Therapeutics, Inc.

About

August J. Moretti served as 4DMT's Chief Financial Officer since January 2019 and announced his retirement as Chief Financial Officer and Assistant Secretary effective September 11, 2023, continuing as a Senior Business Advisor through the end of 2023 and then as a consultant through December 31, 2024. His retirement was not the result of any disagreement with the Company.

Mr. Moretti previously served as Chief Financial Officer at Assertio Therapeutics (formerly Depomed, Inc.) from January 2012 until August 2018. From 2004 to December 2011, he served as Chief Financial Officer and Senior Vice President of Alexza Pharmaceuticals, Inc. From 2001 to 2004, he was Chief Financial Officer and General Counsel of Alavita, Inc., and from 1982 to 2000 he was a partner in an international law firm.

Mr. Moretti received his B.A. in Economics from Princeton University in 1972 and his J.D. from Harvard Law School in 1975.

Since 2019
Tenure 7 yrs

Also at 4D Molecular Therapeutics, Inc.

DM David Kirn, M.D. Co-Founder, President, Chief Executive Officer and Director JP John F. Milligan, Ph.D. Director and Executive Chairman JM Jacob Chacko, M.D., MBA Director SM Susannah Gray, MBA Director CP Charles P. Theuer, M.D., Ph.D. Director NM Nancy Miller-Rich Director

Roles

Organization Role Dates Details
4D Molecular Therapeutics, Inc. Former Chief Financial Officer 2019–present Current role
Assertio Therapeutics (formerly Depomed, Inc.) Chief Financial Officer 2012-2018 CFO from January 2012 until August 2018.
Alexza Pharmaceuticals, Inc. Chief Financial Officer and Senior Vice President 2004-2011 From 2004 to December 2011.
Alavita, Inc. Chief Financial Officer and General Counsel 2001-2004 From 2001 to 2004.
International law firm Partner 1982-2000 Partner in an international law firm from 1982 to 2000.

Related

Source: 4D Molecular Therapeutics, Inc. proxy statement (SEC Schedule 14A)

Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.

See how VectorShift works for your firm

Request Demo